🇯🇵 日本語 🇺🇸 English
3,791 companies 2,399 AI summaries 1,857 risk analyses 1,326 growth scores Register free — watchlist & alerts →
EDINET 6678 Neutral Risk Analyzed 📈 Growth 4/10

Techno Medica Co.,Ltd.

Annual Securities Report - 39th Term(2025/04/01 - 2026/03/31) ／ 2026-06-23 11:05

Covers EDINET statutory filings (TDNET timely disclosures / earnings flashes are not included).

EarningsGuidance DownDividend UpNew ProductNew MarketDemand
AI Summary 2026-06-23 11:11

FY2026 (Mar 2026): Revenue +13.4% (¥11,236M) and OP +28.3% (¥1,668M) achieved. Blood collection system devices surged +34.5%, but next FY guidance shows sharp decline with Revenue -8.3%, OP -34.1%. Market saturation and worsening healthcare facility finances pose headwinds.

KEY POINTS
  • FY2026 Revenue +13.4% (¥9,906M → ¥11,236M), OP +28.3% (¥1,300M → ¥1,668M) achieved growth
  • Blood collection systems surged +34.4% but next FY guidance signals sharp -8.3% revenue, -34.1% OP decline
  • Domestic market share ~90% for blood collection systems; new unit shipments facing saturation, growth ceiling expected
📊 Revenue
Revenue +13.4% (¥9,906M → ¥11,236M)
💰 Operating profit
OP +28.3% (¥1,300M → ¥1,668M)
🔮 Outlook
FY2027 outlook: Revenue ¥10.3B (-8.3%), OP ¥1.1B (-34.1%). Mid-term 2026 plan targets ¥32.1B revenue and ¥3.77B OP over 3-year cumulative (2027-2029).
📈 Growth outlook 📈 Growth 4/10
Blood collection systems hold ~90% domestic market share; limited new unit growth ahead. Next FY revenue decline of -8.3% reflects market saturation. Shift to new products and markets essential for sustainable growth.
Growth drivers
  • Blood collection systems & consumables represent ~70% of revenue with 2,500+ domestic facility installations
  • Consumables show steady growth with installed base expansion, though raw material inflation pressures pricing
  • New product development (healthcare & medical solutions) and international expansion targeted as growth drivers
  • Specimen analysis devices declined -15.1% YoY amid intense domestic competition
Risk and growth scores and tags are AI-generated estimates from analyzing the disclosure. They are not guarantees of fact, nor investment advice or recommendations. Make investment decisions at your own discretion.
⚠️ Extracted Risk Factors
CategoryDescriptionScoreNew
Earnings Deterioration Risk Next FY guidance shows sharp revenue decline -8.3% and OP fall -34.1%. Healthcare facility investment squeeze driven by worsening medical finance outlook. 8/10
Market Risk Blood collection systems hold ~90% domestic market share; new unit demand saturation approaching due to limited target hospital base. Market cap growth outlook constrained. 7/10
Customer Concentration Risk Primary end-customers are hospitals; main distribution channel via medical wholesalers. Healthcare funding contraction poses significant sales slowdown risk. 7/10
Raw Material Risk Heavy reliance on plastic materials for consumables manufacturing. Oil price volatility and raw material shortages risk supply disruption and cost inflation. 6/10
Competitive Intensity Risk Specimen analysis devices face pricing pressure from competitors (sales -15.1%). Blood collection systems threatened by third-party consumables undercutting pure parts pricing. 6/10
Regulatory Risk Subject to Pharmaceutical Affairs Law, QMS ordinance and related regulations for medical devices and in vitro diagnostics. Law changes and compliance violations pose operational risks. 5/10
Supply Chain Risk Manufacturing of core devices outsourced to contract manufacturers. Loss of key supplier or production disruption poses delivery and revenue interruption risk. 5/10
Climate Change Risk Large-scale disasters could severely impact operations and facilities. BCP measures in place but complete mitigation challenging given manufacturing concentration. 4/10
8/10 Earnings Deterioration Risk
Next FY guidance shows sharp revenue decline -8.3% and OP fall -34.1%. Healthcare facility investment squeeze driven by worsening medical finance outlook.
7/10 Market Risk
Blood collection systems hold ~90% domestic market share; new unit demand saturation approaching due to limited target hospital base. Market cap growth outlook constrained.
7/10 Customer Concentration Risk
Primary end-customers are hospitals; main distribution channel via medical wholesalers. Healthcare funding contraction poses significant sales slowdown risk.
6/10 Raw Material Risk
Heavy reliance on plastic materials for consumables manufacturing. Oil price volatility and raw material shortages risk supply disruption and cost inflation.
6/10 Competitive Intensity Risk
Specimen analysis devices face pricing pressure from competitors (sales -15.1%). Blood collection systems threatened by third-party consumables undercutting pure parts pricing.
5/10 Regulatory Risk
Subject to Pharmaceutical Affairs Law, QMS ordinance and related regulations for medical devices and in vitro diagnostics. Law changes and compliance violations pose operational risks.
5/10 Supply Chain Risk
Manufacturing of core devices outsourced to contract manufacturers. Loss of key supplier or production disruption poses delivery and revenue interruption risk.
4/10 Climate Change Risk
Large-scale disasters could severely impact operations and facilities. BCP measures in place but complete mitigation challenging given manufacturing concentration.
X LinkedIn Threads Bluesky Facebook
Track Japanese disclosures with JSIGNAL

AI summaries, risk & growth analysis, watchlist alerts and a screener for every Japanese listed company.

Start free — 30-day trial Login